Skip to main content
NASDAQ:VIE

Viela Bio News Headlines

Notice: This company has been marked as potentially delisted and may not be actively trading.
$53.01
0.00 (0.00 %)
(As of 03/15/2021)
Add
Compare
Today's Range
$53.01
$53.01
50-Day Range
$52.92
$53.20
52-Week Range
$25.02
$65.00
VolumeN/A
Average Volume1.07 million shs
Market Capitalization$2.91 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.43

Headlines

Viela Bio (NASDAQ VIE) News Headlines Today

SourceHeadline
Horizons (HZNP) Q1 Earnings Miss Estimates, Revenues BeatHorizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat
nasdaq.com - May 6 at 11:18 AM
Horizon Therapeutics PLC (HZNP) Q1 2021 Earnings Call TranscriptHorizon Therapeutics PLC (HZNP) Q1 2021 Earnings Call Transcript
msn.com - May 5 at 6:32 PM
BRIEF-Horizon Therapeutics Reports Qtrly Adjusted Earnings Per Share $0.03BRIEF-Horizon Therapeutics Reports Qtrly Adjusted Earnings Per Share $0.03
msn.com - May 5 at 8:29 AM
AstraZeneca Q1 Profit Climbs - Quick FactsAstraZeneca Q1 Profit Climbs - Quick Facts
nasdaq.com - April 30 at 5:51 PM
3 Reasons to Buy Horizon Therapeutics Stock and 1 Not To3 Reasons to Buy Horizon Therapeutics Stock and 1 Not To
nasdaq.com - April 17 at 8:24 AM
Emerging Drugs for the Acute Lung Injury Treatment: A Focus on Recent Clinical TrialsEmerging Drugs for the Acute Lung Injury Treatment: A Focus on Recent Clinical Trials
benzinga.com - March 16 at 10:33 AM
Viela Bio closes $3.1B sale to European pharmaceutical companyViela Bio closes $3.1B sale to European pharmaceutical company
bizjournals.com - March 15 at 6:41 PM
Recap: Viela Bio Q4 EarningsRecap: Viela Bio Q4 Earnings
finance.yahoo.com - March 1 at 11:17 PM
Heres what to expect from Viela Bios earnings reportHere's what to expect from Viela Bio's earnings report
markets.businessinsider.com - February 27 at 1:37 PM
Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 ForumViela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum
finance.yahoo.com - February 25 at 11:23 AM
Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021
finance.yahoo.com - February 22 at 7:49 AM
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of VIE, FFG, JWS, and RNET MergersSHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of VIE, FFG, JWS, and RNET Mergers
finance.yahoo.com - February 19 at 12:58 PM
Can Horizon Pharma Stock Continue Higher After 25% Gains In 10 Days?Can Horizon Pharma Stock Continue Higher After 25% Gains In 10 Days?
nasdaq.com - February 18 at 9:59 AM
SHAREHOLDER ALERT: WeissLaw LLP Reminds CUB, CRHM, VIE, and SPRQ Shareholders About Its Ongoing InvestigationsSHAREHOLDER ALERT: WeissLaw LLP Reminds CUB, CRHM, VIE, and SPRQ Shareholders About Its Ongoing Investigations
finance.yahoo.com - February 15 at 9:57 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Viela Bio, Inc. - VIESHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Viela Bio, Inc. - VIE
finance.yahoo.com - February 12 at 11:19 PM
Viela Bio Inc Registered Shs NeutralViela Bio Inc Registered Shs Neutral
markets.businessinsider.com - February 10 at 10:47 PM
Wedbush Downgrades Viela Bio to NeutralWedbush Downgrades Viela Bio to Neutral
benzinga.com - February 8 at 7:29 PM
VIELA BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Viela Bio, Inc. - VIEVIELA BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Viela Bio, Inc. - VIE
finance.yahoo.com - February 4 at 2:54 PM
Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVAs Encouraging Drug Data & MoreBiotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More
finance.yahoo.com - February 3 at 12:28 PM
Horizon Therapeutics to buy Viela Bio for about $3.05 billionHorizon Therapeutics to buy Viela Bio for about $3.05 billion
reuters.com - February 3 at 7:27 AM
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Viela Bio, Inc (NASDAQ - VIE)SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Viela Bio, Inc (NASDAQ - VIE)
finance.yahoo.com - February 2 at 8:14 PM
Horizon To Snap Up Viela Bio For $3B; Shares ClimbHorizon To Snap Up Viela Bio For $3B; Shares Climb
finance.yahoo.com - February 2 at 10:05 AM
Stock Alert: Viela Bio Rises 52% On News Of AcquisitionStock Alert: Viela Bio Rises 52% On News Of Acquisition
nasdaq.com - February 1 at 6:14 PM
Horizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela buyHorizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela buy
reuters.com - February 1 at 6:14 PM
UPDATE 1-Horizon Therapeutics boosts rare-disease portfolio with $3.05 bln Viela Bio buyUPDATE 1-Horizon Therapeutics boosts rare-disease portfolio with $3.05 bln Viela Bio buy
reuters.com - February 1 at 1:14 PM
Viela Bio to be acquired for $3.1 billionViela Bio to be acquired for $3.1 billion
bizjournals.com - February 1 at 1:14 PM
Viela Bio Spikes as Horizon Therapeutics Agrees to Acquire It for $3.5 BillionViela Bio Spikes as Horizon Therapeutics Agrees to Acquire It for $3.5 Billion
msn.com - February 1 at 1:14 PM
Viela Bio Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Viela Bio, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – VIEViela Bio Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Viela Bio, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – VIE
finance.yahoo.com - February 1 at 1:14 PM
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Viela Bio, Inc. BuyoutSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Viela Bio, Inc. Buyout
finance.yahoo.com - February 1 at 1:14 PM
Why Viela Bio Stock Is Skyrocketing TodayWhy Viela Bio Stock Is Skyrocketing Today
finance.yahoo.com - February 1 at 1:14 PM
AstraZeneca To Get Up To USD780 Million From Horizons Viela TakeoverAstraZeneca To Get Up To USD780 Million From Horizon's Viela Takeover
lse.co.uk - February 1 at 8:13 AM
Horizon Therapeutics To Buy Viela Bio For $53/Shr Cash - Quick FactsHorizon Therapeutics To Buy Viela Bio For $53/Shr Cash - Quick Facts
nasdaq.com - February 1 at 8:13 AM
Horizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela Bio buyHorizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela Bio buy
reuters.com - February 1 at 8:13 AM
Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billionHorizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billion
msn.com - February 1 at 8:13 AM
Horizon Therapeutics to Purchase Viela Bio for $3.1 BillionHorizon Therapeutics to Purchase Viela Bio for $3.1 Billion
msn.com - February 1 at 8:13 AM
Were Hopeful That Viela Bio (NASDAQ:VIE) Will Use Its Cash WiselyWe're Hopeful That Viela Bio (NASDAQ:VIE) Will Use Its Cash Wisely
finance.yahoo.com - January 26 at 3:11 PM
Is Viela Bio (VIE) A Good Stock To Buy Now?Is Viela Bio (VIE) A Good Stock To Buy Now?
finance.yahoo.com - December 2 at 3:26 PM
Viela Bio: Startup With A Head StartViela Bio: Startup With A Head Start
seekingalpha.com - November 23 at 12:54 PM
Viela Bio, Inc. 2020 Q3 - Results - Earnings Call PresentationViela Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation
seekingalpha.com - November 16 at 4:52 AM
The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On TapThe Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap
msn.com - November 11 at 8:33 AM
Viela Bio, Inc. (VIE) CEO Bing Yao on Q3 2020 Results - Earnings Call TranscriptViela Bio, Inc. (VIE) CEO Bing Yao on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 11 at 8:33 AM
Viela Bio Inc (VIE) Q3 2020 Earnings Call TranscriptViela Bio Inc (VIE) Q3 2020 Earnings Call Transcript
fool.com - November 11 at 3:41 AM
VIELA BIO EPS beats by $0.08, misses on revenueVIELA BIO EPS beats by $0.08, misses on revenue
seekingalpha.com - November 10 at 6:36 PM
Viela Bio Reports Third Quarter 2020 Financial Results and Program HighlightsViela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
finance.yahoo.com - November 10 at 6:36 PM
Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus ErythematosusViela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
finance.yahoo.com - November 5 at 6:53 PM
Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020
finance.yahoo.com - November 2 at 10:41 AM
Analyst Forecasts Just Became More Bearish On Viela Bio, Inc. (NASDAQ:VIE)Analyst Forecasts Just Became More Bearish On Viela Bio, Inc. (NASDAQ:VIE)
finance.yahoo.com - October 28 at 10:01 AM
Viela Bio Inc Registered Shs BuyViela Bio Inc Registered Shs Buy
markets.businessinsider.com - October 27 at 6:10 PM
Viela Bio Inc (VIE) Investor Presentation - SlideshowViela Bio Inc (VIE) Investor Presentation - Slideshow
seekingalpha.com - September 15 at 3:18 PM
Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020
finance.yahoo.com - September 3 at 6:53 PM
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.